- dot.LA
- Posts
- Transforming LA into a Biotech Hub
Transforming LA into a Biotech Hub
Could Los Angeles truly emerge as a biotech hub comparable to South San Francisco and Boston?
Christine Rothacker
June 05, 2024
Image Source: UCLA Health
Skeptics once doubted the feasibility of a high-speed rail connecting LA to Las Vegas, but now it's becoming a reality. Perhaps all it takes is the right team to turn the improbable into the possible.
LA County has invested millions to establish itself as a biotech hub, including funding the nonprofit BioscienceLA and its BioFutures program. The county's investments have also created a supportive infrastructure with initiatives like the 20,000-square-foot BioscienceLA office in Culver City, generating significant economic activity and jobs. However, despite these efforts, LA has remained a secondary market for biotech and life sciences due to geographic sprawl and limited supply of life science/biotech space, even though the region boasts significant life science talent.
Life Science Degree Completions by Vacancy Comparison
A leading figure in the biotech scene in Los Angeles is the impressive biotech entrepreneur, Arie Belldegrun. Belldegrun has played a significant role in the successful exits of Agensys, Cougar Biotechnology, and Kite Pharma, which collectively sold for $13.4 billion. An Israeli-born urologist and immunology researcher, Belldegrun has been instrumental in building the biotech sector in Los Angeles. Utilizing proceeds from these exits, he established Bellco Capital, which primarily invests in life science and real estate companies, and co-founded several biotech-focused funds and ventures.
Belldegrun's efforts have culminated in the creation of the California Institute for Immunology and Immunotherapy at the former Westside Pavilion in Westwood, in collaboration with other prominent figures and philanthropists. The 700,000-square-foot property, acquired at the end of 2023, will also house the UCLA Center for Quantum Science & Engineering. “The goal is to build the immunology equivalent of Silicon Valley in Los Angeles,” says UCLA Health CEO John Mazziotta, MD, PhD. The center will hold its own patents and will eventually foster new biotech startups through its incubator and accelerator programs. The initiative has secured $500 million in state funding and plans to raise an additional $1 billion, positioning Los Angeles to become a leading biotech hub alongside regions like the Bay Area, San Diego, and Boston. Despite challenges posed by the city's geographic sprawl, these combined efforts by leaders like Belldegrun and county programs are transforming LA's biotech landscape, fostering a thriving environment for future scientific and commercial successes.
    |